Last reviewed · How we verify
TJO-018 (HA 0.15%)
TJO-018 is a hyaluronic acid-based topical formulation that provides lubrication and moisture retention to the ocular surface.
TJO-018 is a hyaluronic acid-based topical formulation that provides lubrication and moisture retention to the ocular surface. Used for Dry eye disease / Keratoconjunctivitis sicca.
At a glance
| Generic name | TJO-018 (HA 0.15%) |
|---|---|
| Sponsor | Taejoon Pharmaceutical Co., Ltd. |
| Drug class | Artificial tear / Ocular lubricant |
| Target | Ocular surface (non-receptor mediated) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Hyaluronic acid (HA) is a naturally occurring polysaccharide that acts as a humectant, binding water to maintain corneal hydration and protect the epithelial surface. At 0.15% concentration, it reduces friction between the eyelid and cornea, alleviates dry eye symptoms, and promotes corneal healing through its viscoelastic properties.
Approved indications
- Dry eye disease / Keratoconjunctivitis sicca
Common side effects
- Ocular irritation
- Transient blurred vision
- Eye discomfort
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TJO-018 (HA 0.15%) CI brief — competitive landscape report
- TJO-018 (HA 0.15%) updates RSS · CI watch RSS
- Taejoon Pharmaceutical Co., Ltd. portfolio CI